Trial Profile
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Assess the Safety and Efficacy of ASP1650, a Monoclonal Antibody Targeting Claudin 6 (CLDN6), in Male Subjects With Incurable Platinum Refractory Germ Cell Tumors
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Jul 2022
Price :
$35
*
At a glance
- Drugs IMAB 027 (Primary)
- Indications Germ cell and embryonal neoplasms; Germ cell cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Astellas Pharma Global Development
- 27 Jun 2022 Results published in the Investigational New Drugs
- 04 Nov 2020 Status changed from recruiting to completed.
- 03 Oct 2020 Planned End Date changed from 1 Oct 2022 to 1 Feb 2021.